Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Karoly Nikolich
AddedMar 31, 2024
UpdatedMay 31, 2026
Karoly Nikolich

Karoly Nikolich

Board Member, Neuropore Therapies

CrunchbaseLinkedIn

Karoly Nikolich's Career

Neuropore Therapies
Neuropore Therapies

San Diego, CA, US

Board Member· Board
AGY Therapeutics
AGY Therapeutics

San Francisco, CA, US

Founder
MapLight Therapeutics
MapLight Therapeutics

Palo Alto, CA, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Karoly Nikolich's Career

Neuropore Therapies
Neuropore Therapies
Pre-Seed$500k132008San Diego, CA, US
Board Member· Board

Similar to Neuropore Therapies

NeuroTherapeutics PharmaNeuroTherapeutics PharmaChicago, IL, USPharmaceuticals, Therapeuticsest. 2006NeuroTherapeutics PharmaChicago, IL, US · est. 2006

NeuroTherapeutics Pharma: A US-based biopharmaceutical firm specializing in neuropathic and acute pain treatments.

Public · $60.7M30
Orphan Star TherapeuticsOrphan Star TherapeuticsNew York City, NY, USTherapiesest. 2017Orphan Star TherapeuticsNew York City, NY, US · est. 2017

Orphan Star Therapeutics: A NY-based biopharmaceutical firm developing therapies for rare diseases.

Series B · $20M5
Mojave PharmaMojave PharmaLas Vegas, NV, USTherapeuticsest. 2013Mojave PharmaLas Vegas, NV, US · est. 2013

Mojave Pharma: Pioneering novel therapies for neurodegenerative & psychiatric diseases.

Series C · $525M175
NeurolinkNeurolinkSan Antonio, TX, USMedical Devicesest. 2008NeurolinkSan Antonio, TX, US · est. 2008

Neurolink Medical, Inc.: Pioneering CNS disorder treatments from San Jose, California.

Seed · $3.9M23
AGY Therapeutics
AGY Therapeutics
Series C$22M751998San Francisco, CA, US
Founder

Similar to AGY Therapeutics

MapLight TherapeuticsMapLight TherapeuticsPalo Alto, CA, USDrug Discovery, Therapeuticsest. 2018MapLight TherapeuticsPalo Alto, CA, US · est. 2018

Maplight: A biopharmaceutical firm innovating CNS disorder therapeutics via drug discovery platform.

Series C · $268.1M67
PolyCore TherapeuticsPolyCore TherapeuticsPará, BRCNS Treatmentsest. 2015PolyCore TherapeuticsPará, BR · est. 2015

PolyCore Therapeutics: Innovating breakthrough CNS disease treatments through dedicated life science research.

Seed · $6.5M11
Psy TherapeuticsPsy TherapeuticsBoston, MA, USDrug Developmentest. 2012Psy TherapeuticsBoston, MA, US · est. 2012

Psy Therapeutics: Innovating novel medicines for CNS disorders like anxiety, depression, and dementia.

Seed · $4M30
MapLight Therapeutics
MapLight Therapeutics
Series C$268.1M672018Palo Alto, CA, US
Co-Founder

Leadership at MapLight Therapeutics

Karl DeisserothKarl DeisserothCo-Founder
Chris KroegerChris KroegerBoard Member

Karoly Nikolich's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to Karoly Nikolich

Steven BraithwaiteSteven BraithwaiteCo-Founder · MentiNovaNikil ViswanathanNikil ViswanathanCo-Founder · AlchemyFabio GrattonFabio GrattonCo-Founder · Carma ProjectLeonide SaadLeonide SaadCo-Founder · Alkeus PharmaceuticalsKirthi RamakrishnanKirthi RamakrishnanBoard Member · ManokéAlex ShootmanAlex ShootmanBoard Member · Alkami Technology